Portal de Periódicos da CAPES

Innovative therapeutics for inflammatory bowel disease

2007; Baishideng Publishing Group; Volume: 13; Issue: 13 Linguagem: Inglês

10.3748/wjg.v13.i13.1893

2219-2840

Jesús K. Yamamoto‐Furusho,

Celiac Disease Research and Management

I n f l a m m a t o r y b o w e l dis e as e s (I B D ) a r e c hr o nic inflammatory conditions of the gastrointestinal tract, which clinically present as one of two disorders, Crohn's disease or ulcerative colitis.Mainstays of drug treatments for IBD include aminosalicylates, corticosteroids and immunosuppressants such as azathioprine, methotrexate and cyclosporin.Advances in basic research of the pathophysiological process in IBD have been applied to generate a variety of new therapeutics targeting at different levels of the inflammatory processes.New therapies are classified as: (1) Anti-TNFα antibodies; (2) Recombinant cytokines; (3) Selective adhesion blockade; (4) Growth factors; (5) Innate immunostimulation; (6) Nucleic acid based therapies; (7) Gene therapy; (8) Autologous bone-marrow transplantation; (9) Helminths and (10) Extracorporeal immunomodulation.All treatments have the potential to provide more effective and safe treatment for IBD.